Form 4 for ANTX AN2 Therapeutics, Inc.

Accepted 2026-02-23 00:00:00 ET · period of report 2026-02-20 · accession 0001193125-26-064141 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-02-23	2026-02-20	ANTX	Chanda Sanjay	Chief Development Off	A - Grant	$0.00	+38.0K	118.8K	+47%	$0
D	2026-02-23	2026-02-20	ANTX	Chanda Sanjay	Chief Development Off	A - Grant	$0.00	+77.0K	77.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-02-20	A	A	38,000	$0.00	118,823	D	—	—	(F1) Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. (F3) Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025. (F2) Includes a balance of (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date.
2	Derivative	Stock Option (right to buy)	2026-02-20	A	A	77,000	$0.00	77,000	D	$1.04 · — to 2036-02-19	77,000 Common Stock	(F4) The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.